CA2608362A1 - 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same - Google Patents
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same Download PDFInfo
- Publication number
- CA2608362A1 CA2608362A1 CA002608362A CA2608362A CA2608362A1 CA 2608362 A1 CA2608362 A1 CA 2608362A1 CA 002608362 A CA002608362 A CA 002608362A CA 2608362 A CA2608362 A CA 2608362A CA 2608362 A1 CA2608362 A1 CA 2608362A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- naphthyridine
- carbonitrile
- compound according
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 128
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 title claims description 13
- 239000003112 inhibitor Substances 0.000 title description 4
- DMNOLIMFCNADKN-UHFFFAOYSA-N 4,6-diamino-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(N)=CC2=C1N DMNOLIMFCNADKN-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 100
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 10
- -1 C(O)N(C1-6 alkyl)2 Chemical group 0.000 claims description 78
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- SQYJTFOFYFPFAZ-UHFFFAOYSA-N 4-(3-bromoanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound BrC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 SQYJTFOFYFPFAZ-UHFFFAOYSA-N 0.000 claims description 2
- JUUSDSKOIBWSDA-UHFFFAOYSA-N 4-(3-bromoanilino)-6-[(4-methoxyphenyl)methylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1CNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=CC(Br)=C1 JUUSDSKOIBWSDA-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 23
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 174
- 238000005481 NMR spectroscopy Methods 0.000 description 108
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 99
- 239000000047 product Substances 0.000 description 79
- 239000012043 crude product Substances 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 71
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
- 239000007787 solid Substances 0.000 description 54
- 238000003818 flash chromatography Methods 0.000 description 49
- 238000002953 preparative HPLC Methods 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- XJFIAYNKSIJCTA-UHFFFAOYSA-N 4-chloro-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1Cl XJFIAYNKSIJCTA-UHFFFAOYSA-N 0.000 description 29
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- 239000002904 solvent Substances 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 20
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- QONCFNVAJYDZDL-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(F)C(Cl)=C1 QONCFNVAJYDZDL-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 16
- 238000010626 work up procedure Methods 0.000 description 16
- LKSJXDPHTNUEIJ-UHFFFAOYSA-N 1,8-naphthyridine-3-carbonitrile Chemical compound N1=CC=CC2=CC(C#N)=CN=C21 LKSJXDPHTNUEIJ-UHFFFAOYSA-N 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000004093 cyano group Chemical group *C#N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 125000001188 haloalkyl group Chemical group 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- HXCQYVUZKIRAMC-UHFFFAOYSA-N 4-(4-chloro-3-fluoroanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(Cl)C(F)=C1 HXCQYVUZKIRAMC-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 9
- 229940093475 2-ethoxyethanol Drugs 0.000 description 9
- BNHNCJLIRXIIBC-UHFFFAOYSA-N 6-fluoro-4-(3-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound CC(C)C1=CC=CC(NC=2C3=CC(F)=NC=C3N=CC=2C#N)=C1 BNHNCJLIRXIIBC-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- LWMOKTLVXAZYSA-UHFFFAOYSA-N 4-(4-benzylanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=C1)=CC=C1CC1=CC=CC=C1 LWMOKTLVXAZYSA-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- LZLYEUTYAVIPML-UHFFFAOYSA-N 1,7-naphthyridine-3-carbonitrile Chemical compound C1=NC=CC2=CC(C#N)=CN=C21 LZLYEUTYAVIPML-UHFFFAOYSA-N 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 125000004043 oxo group Chemical group O=* 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- SQTUCYUSPYPKEJ-UHFFFAOYSA-N 4-(3,5-dichloroanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC(Cl)=CC(Cl)=C1 SQTUCYUSPYPKEJ-UHFFFAOYSA-N 0.000 description 4
- VVVDJJLYLRQBCA-UHFFFAOYSA-N 4-(3-bromo-4-methylanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Br)C(C)=CC=C1NC1=C(C#N)C=NC2=CN=C(F)C=C12 VVVDJJLYLRQBCA-UHFFFAOYSA-N 0.000 description 4
- FNQSNCRSTNLGFE-UHFFFAOYSA-N 4-(3-iodoanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound IC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 FNQSNCRSTNLGFE-UHFFFAOYSA-N 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 3
- QILHGSSOWXKYFZ-UHFFFAOYSA-N 3-fluoro-1,8-naphthyridine Chemical compound N1=CC=CC2=CC(F)=CN=C21 QILHGSSOWXKYFZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical group O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical group O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 2
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 2
- UGFVXLSTOIXXCY-UHFFFAOYSA-N 3-[(3-cyano-6-fluoro-1,7-naphthyridin-4-yl)amino]benzamide Chemical compound NC(=O)C1=CC=CC(NC=2C3=CC(F)=NC=C3N=CC=2C#N)=C1 UGFVXLSTOIXXCY-UHFFFAOYSA-N 0.000 description 2
- DQXZLTRHDFXOTA-UHFFFAOYSA-N 3-[[3-cyano-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridin-4-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 DQXZLTRHDFXOTA-UHFFFAOYSA-N 0.000 description 2
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- FRGVPXYKUSAZGI-UHFFFAOYSA-N 4-(3,4-dichloroanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 FRGVPXYKUSAZGI-UHFFFAOYSA-N 0.000 description 2
- AUKHEGUMCXKMSE-UHFFFAOYSA-N 4-(3,4-difluoroanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(F)C(F)=C1 AUKHEGUMCXKMSE-UHFFFAOYSA-N 0.000 description 2
- CSSCHRSHGMWCGX-UHFFFAOYSA-N 4-(4-anilinoanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=C1)=CC=C1NC1=CC=CC=C1 CSSCHRSHGMWCGX-UHFFFAOYSA-N 0.000 description 2
- JHXBDBQSMXPFMK-UHFFFAOYSA-N 4-(4-chloroanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(Cl)C=C1 JHXBDBQSMXPFMK-UHFFFAOYSA-N 0.000 description 2
- SIADAGFXEHBPGG-UHFFFAOYSA-N 4-chloro-1,8-naphthyridine Chemical compound C1=CC=C2C(Cl)=CC=NC2=N1 SIADAGFXEHBPGG-UHFFFAOYSA-N 0.000 description 2
- WHYHKGYGDISKFA-UHFFFAOYSA-N 4-chloro-3,6-difluoro-2h-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1(F)CN=C2C=NC(F)=CC2=C1Cl WHYHKGYGDISKFA-UHFFFAOYSA-N 0.000 description 2
- ZWTCXXMYRHNQPF-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(3-nitroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound [O-][N+](=O)C1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 ZWTCXXMYRHNQPF-UHFFFAOYSA-N 0.000 description 2
- VBQFAKQZRFNZRE-UHFFFAOYSA-N 6-fluoro-4-(1h-indol-5-ylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C2NC=CC2=CC(NC2=C3C=C(N=CC3=NC=C2C#N)F)=C1 VBQFAKQZRFNZRE-UHFFFAOYSA-N 0.000 description 2
- JEROMYKCTQYJOI-UHFFFAOYSA-N 6-fluoro-4-(3-iodoanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=CC(I)=C1 JEROMYKCTQYJOI-UHFFFAOYSA-N 0.000 description 2
- FRFAAPWCMJVZEZ-UHFFFAOYSA-N 6-fluoro-4-(3-nitroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound [O-][N+](=O)C1=CC=CC(NC=2C3=CC(F)=NC=C3N=CC=2C#N)=C1 FRFAAPWCMJVZEZ-UHFFFAOYSA-N 0.000 description 2
- XZUXLVMEEDLDBZ-UHFFFAOYSA-N 6-fluoro-4-(4-fluoroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1NC1=C(C#N)C=NC2=CN=C(F)C=C12 XZUXLVMEEDLDBZ-UHFFFAOYSA-N 0.000 description 2
- ZXQRSRJQGDZAJT-UHFFFAOYSA-N 6-fluoro-4-(4-nitroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=C(C#N)C=NC2=CN=C(F)C=C12 ZXQRSRJQGDZAJT-UHFFFAOYSA-N 0.000 description 2
- QHYJTSAHXFIUMC-UHFFFAOYSA-N 6-fluoro-4-(4-phenylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=C1)=CC=C1C1=CC=CC=C1 QHYJTSAHXFIUMC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101100314299 Listeria innocua serovar 6a (strain ATCC BAA-680 / CLIP 11262) tpi-2 gene Proteins 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical group C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- OBEFNIRFWUXFRP-UHFFFAOYSA-N methyl 3-[(3-cyano-6-fluoro-1,7-naphthyridin-4-yl)amino]benzoate Chemical compound COC(=O)C1=CC=CC(NC=2C3=CC(F)=NC=C3N=CC=2C#N)=C1 OBEFNIRFWUXFRP-UHFFFAOYSA-N 0.000 description 2
- WDQCPQTVFCFUMO-UHFFFAOYSA-N methyl 3-[[3-cyano-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridin-4-yl]amino]benzoate Chemical compound COC(=O)C1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 WDQCPQTVFCFUMO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical group C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Chemical group 0.000 description 2
- KCQJLTOSSVXOCC-UHFFFAOYSA-N tributyl(prop-1-ynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC KCQJLTOSSVXOCC-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- JRZGPXSSNPTNMA-SNVBAGLBSA-N (1r)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2[C@H](N)CCCC2=C1 JRZGPXSSNPTNMA-SNVBAGLBSA-N 0.000 description 1
- AQFLVLHRZFLDDV-SECBINFHSA-N (1r)-1-phenylpropan-1-amine Chemical compound CC[C@@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-SECBINFHSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 description 1
- JRZGPXSSNPTNMA-JTQLQIEISA-N (1s)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2[C@@H](N)CCCC2=C1 JRZGPXSSNPTNMA-JTQLQIEISA-N 0.000 description 1
- AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 description 1
- XJEVHMGJSYVQBQ-VIFPVBQESA-N (1s)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@@H](N)CCC2=C1 XJEVHMGJSYVQBQ-VIFPVBQESA-N 0.000 description 1
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 1
- RBKHNGHPZZZJCI-UHFFFAOYSA-N (4-aminophenyl)-phenylmethanone Chemical compound C1=CC(N)=CC=C1C(=O)C1=CC=CC=C1 RBKHNGHPZZZJCI-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 0 *N(*)c(cc12)ncc1ncc(C#N)c2N(*)* Chemical compound *N(*)c(cc12)ncc1ncc(C#N)c2N(*)* 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical class C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- KBIXYFABFIYSAU-UHFFFAOYSA-N 2-(aminomethyl)-3-fluoroaniline Chemical compound NCC1=C(N)C=CC=C1F KBIXYFABFIYSAU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- YUMCAWUAVINQTG-UHFFFAOYSA-N 2-fluoro-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(F)=CC=C21 YUMCAWUAVINQTG-UHFFFAOYSA-N 0.000 description 1
- XOZAJNLUAODXSP-UHFFFAOYSA-N 2-fluoro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)N=C1 XOZAJNLUAODXSP-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- GELMWIVBBPAMIO-UHFFFAOYSA-N 2-methylbutan-2-amine Chemical compound CCC(C)(C)N GELMWIVBBPAMIO-UHFFFAOYSA-N 0.000 description 1
- CLAGARRWBBUZDR-UHFFFAOYSA-N 2-morpholin-4-yl-1-phenylethanamine Chemical compound C=1C=CC=CC=1C(N)CN1CCOCC1 CLAGARRWBBUZDR-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 1
- SADHVOSOZBAAGL-UHFFFAOYSA-N 3-(trifluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)(F)F)=C1 SADHVOSOZBAAGL-UHFFFAOYSA-N 0.000 description 1
- YOEMJZCYWGWOHH-UHFFFAOYSA-N 3-[[3-cyano-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridin-4-yl]amino]benzamide Chemical compound NC(=O)C1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 YOEMJZCYWGWOHH-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- GRXMMIBZRMKADT-UHFFFAOYSA-N 3-bromo-4-methylaniline Chemical compound CC1=CC=C(N)C=C1Br GRXMMIBZRMKADT-UHFFFAOYSA-N 0.000 description 1
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- FFCSRWGYGMRBGD-UHFFFAOYSA-N 3-iodoaniline Chemical compound NC1=CC=CC(I)=C1 FFCSRWGYGMRBGD-UHFFFAOYSA-N 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- UCSYVYFGMFODMY-UHFFFAOYSA-N 3-phenoxyaniline Chemical compound NC1=CC=CC(OC=2C=CC=CC=2)=C1 UCSYVYFGMFODMY-UHFFFAOYSA-N 0.000 description 1
- XCCNRBCNYGWTQX-UHFFFAOYSA-N 3-propan-2-ylaniline Chemical compound CC(C)C1=CC=CC(N)=C1 XCCNRBCNYGWTQX-UHFFFAOYSA-N 0.000 description 1
- BNAFFKOTSISKMR-UHFFFAOYSA-N 4-(3,4-dichloroanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 BNAFFKOTSISKMR-UHFFFAOYSA-N 0.000 description 1
- VSDBTGYVDVVTAV-UHFFFAOYSA-N 4-(3,4-dichloroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 VSDBTGYVDVVTAV-UHFFFAOYSA-N 0.000 description 1
- OSTBQYNQLJPEOJ-UHFFFAOYSA-N 4-(3,4-difluoroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 OSTBQYNQLJPEOJ-UHFFFAOYSA-N 0.000 description 1
- QXGZFXTTXWORPP-UHFFFAOYSA-N 4-(3,5-dichloroanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound ClC1=CC(Cl)=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 QXGZFXTTXWORPP-UHFFFAOYSA-N 0.000 description 1
- ZRGSJYFBYDVDEQ-UHFFFAOYSA-N 4-(3,5-dichloroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound ClC1=CC(Cl)=CC(NC=2C3=CC(NCC=4C=NC=CC=4)=NC=C3N=CC=2C#N)=C1 ZRGSJYFBYDVDEQ-UHFFFAOYSA-N 0.000 description 1
- HHPMRVXXMITTPH-UHFFFAOYSA-N 4-(3-aminoanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound NC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 HHPMRVXXMITTPH-UHFFFAOYSA-N 0.000 description 1
- VJLGIFWZPCKINY-UHFFFAOYSA-N 4-(3-bromo-4-methylanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Br)C(C)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 VJLGIFWZPCKINY-UHFFFAOYSA-N 0.000 description 1
- KXLUGXLMAVTYBV-UHFFFAOYSA-N 4-(3-bromo-4-methylanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Br)C(C)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 KXLUGXLMAVTYBV-UHFFFAOYSA-N 0.000 description 1
- BHBOXNAGNJPQBR-UHFFFAOYSA-N 4-(3-chloro-4-fluoro-n-methylanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC=1C=NC2=CN=C(NCCN3CCOCC3)C=C2C=1N(C)C1=CC=C(F)C(Cl)=C1 BHBOXNAGNJPQBR-UHFFFAOYSA-N 0.000 description 1
- NFIGGNACAOPMBS-UHFFFAOYSA-N 4-(3-chloro-4-fluoro-n-methylanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC=1C=NC2=CN=C(F)C=C2C=1N(C)C1=CC=C(F)C(Cl)=C1 NFIGGNACAOPMBS-UHFFFAOYSA-N 0.000 description 1
- OWIDKBPTIRYEID-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(2-methylbutan-2-ylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NC(C)(C)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 OWIDKBPTIRYEID-UHFFFAOYSA-N 0.000 description 1
- DGOSEVUYZZUPGI-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(2-morpholin-4-ylethoxy)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2OCCN1CCOCC1 DGOSEVUYZZUPGI-UHFFFAOYSA-N 0.000 description 1
- IXQLEZDNYJWUTR-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 IXQLEZDNYJWUTR-UHFFFAOYSA-N 0.000 description 1
- XJWHKUPVYYOETJ-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(3-hydroxypropylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NCCCO)=CC2=C1NC1=CC=C(F)C(Cl)=C1 XJWHKUPVYYOETJ-UHFFFAOYSA-N 0.000 description 1
- NXVAWZCBOMXMGU-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(3-morpholin-4-ylpropylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCCN1CCOCC1 NXVAWZCBOMXMGU-UHFFFAOYSA-N 0.000 description 1
- UZSGXMBGJBAMDX-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(cyclopentylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NC1CCCC1 UZSGXMBGJBAMDX-UHFFFAOYSA-N 0.000 description 1
- LLWVLMFQYQEPJV-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(cyclopropylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NC1CC1 LLWVLMFQYQEPJV-UHFFFAOYSA-N 0.000 description 1
- NMEUKWOOQOHUNA-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 NMEUKWOOQOHUNA-UHFFFAOYSA-N 0.000 description 1
- AVJGIWQXIFOYEK-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-[(4-methoxyphenyl)methylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1CNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=C(F)C(Cl)=C1 AVJGIWQXIFOYEK-UHFFFAOYSA-N 0.000 description 1
- HNDCLVVBDGSSPD-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-[3-(4-methylpiperazin-1-yl)propylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1CN(C)CCN1CCCNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=C(F)C(Cl)=C1 HNDCLVVBDGSSPD-UHFFFAOYSA-N 0.000 description 1
- WLISSBXNPGNOBI-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-[3-(dimethylamino)propylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NCCCN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 WLISSBXNPGNOBI-UHFFFAOYSA-N 0.000 description 1
- JJWPJEKOLAXHRB-NRFANRHFSA-N 4-(3-chloro-4-fluoroanilino)-6-[[(1s)-1-phenylpropyl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=C(F)C(Cl)=C1 JJWPJEKOLAXHRB-NRFANRHFSA-N 0.000 description 1
- XLVOAUQDFLEPIS-SNVBAGLBSA-N 4-(3-chloro-4-fluoroanilino)-6-[[(2r)-2-hydroxypropyl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NC[C@H](O)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 XLVOAUQDFLEPIS-SNVBAGLBSA-N 0.000 description 1
- XLVOAUQDFLEPIS-JTQLQIEISA-N 4-(3-chloro-4-fluoroanilino)-6-[[(2s)-2-hydroxypropyl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NC[C@@H](O)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 XLVOAUQDFLEPIS-JTQLQIEISA-N 0.000 description 1
- INRIOLSBJCIZKM-UHFFFAOYSA-N 4-(3-chloroanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound ClC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 INRIOLSBJCIZKM-UHFFFAOYSA-N 0.000 description 1
- XTWZETQLAMSLKW-UHFFFAOYSA-N 4-(3-chloroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound ClC1=CC=CC(NC=2C3=CC(NCC=4C=NC=CC=4)=NC=C3N=CC=2C#N)=C1 XTWZETQLAMSLKW-UHFFFAOYSA-N 0.000 description 1
- IUXBNURHNHYJTL-UHFFFAOYSA-N 4-(3-cyanoanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 IUXBNURHNHYJTL-UHFFFAOYSA-N 0.000 description 1
- VGLMDBDKNSZAGA-UHFFFAOYSA-N 4-(3-cyanoanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=CC(C#N)=C1 VGLMDBDKNSZAGA-UHFFFAOYSA-N 0.000 description 1
- GXDDKDNMHOWRGZ-UHFFFAOYSA-N 4-(3-fluoroanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound FC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 GXDDKDNMHOWRGZ-UHFFFAOYSA-N 0.000 description 1
- LDOBMKYBQWHFAC-UHFFFAOYSA-N 4-(3-methylanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound CC1=CC=CC(NC=2C3=CC(NCC=4C=NC=CC=4)=NC=C3N=CC=2C#N)=C1 LDOBMKYBQWHFAC-UHFFFAOYSA-N 0.000 description 1
- RXNMGONOXFHEEW-UHFFFAOYSA-N 4-(3-phenoxyanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=C(OC=4C=CC=CC=4)C=CC=3)C(C#N)=CN=C2C=NC=1NCC1=CC=CN=C1 RXNMGONOXFHEEW-UHFFFAOYSA-N 0.000 description 1
- UMNUNNPKLHIZRK-UHFFFAOYSA-N 4-(4-anilinoanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(NC=4C=CC=CC=4)=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCOCC1 UMNUNNPKLHIZRK-UHFFFAOYSA-N 0.000 description 1
- NTHIJYSVQAXLGT-UHFFFAOYSA-N 4-(4-anilinoanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(NC=4C=CC=CC=4)=CC=3)C(C#N)=CN=C2C=NC=1NCC1=CC=CN=C1 NTHIJYSVQAXLGT-UHFFFAOYSA-N 0.000 description 1
- LJEZDKPQCOVDGP-UHFFFAOYSA-N 4-(4-benzoylanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C=C(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)C=CC=1C(=O)C1=CC=CC=C1 LJEZDKPQCOVDGP-UHFFFAOYSA-N 0.000 description 1
- VRRHYYPJPJCBJB-UHFFFAOYSA-N 4-(4-benzoylanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=C1)=CC=C1C(=O)C1=CC=CC=C1 VRRHYYPJPJCBJB-UHFFFAOYSA-N 0.000 description 1
- PXRDIWAVNLQFBI-UHFFFAOYSA-N 4-(4-benzylanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(CC=4C=CC=CC=4)=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCOCC1 PXRDIWAVNLQFBI-UHFFFAOYSA-N 0.000 description 1
- OCKMSSZIMLPJBA-UHFFFAOYSA-N 4-(4-benzylanilino)-6-(2-piperazin-1-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(CC=4C=CC=CC=4)=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCNCC1 OCKMSSZIMLPJBA-UHFFFAOYSA-N 0.000 description 1
- KNHIQYXEQJBASL-UHFFFAOYSA-N 4-(4-benzylanilino)-6-[2-(dimethylamino)ethylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NCCN(C)C)=CC2=C1NC(C=C1)=CC=C1CC1=CC=CC=C1 KNHIQYXEQJBASL-UHFFFAOYSA-N 0.000 description 1
- QHWLITRUEYCQIH-UHFFFAOYSA-N 4-(4-benzylanilino)-6-[3-(4-methylpiperazin-1-yl)propylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1CN(C)CCN1CCCNC(N=CC1=NC=C2C#N)=CC1=C2NC(C=C1)=CC=C1CC1=CC=CC=C1 QHWLITRUEYCQIH-UHFFFAOYSA-N 0.000 description 1
- KLSMBIIKXXYIMP-UHFFFAOYSA-N 4-(4-benzylanilino)-6-[3-(dimethylamino)propylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(NCCCN(C)C)=CC2=C1NC(C=C1)=CC=C1CC1=CC=CC=C1 KLSMBIIKXXYIMP-UHFFFAOYSA-N 0.000 description 1
- NFTPMKVBRPECCV-UHFFFAOYSA-N 4-(4-bromoanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(Br)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 NFTPMKVBRPECCV-UHFFFAOYSA-N 0.000 description 1
- FWZGQFIZUNRVMK-UHFFFAOYSA-N 4-(4-bromoanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(Br)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 FWZGQFIZUNRVMK-UHFFFAOYSA-N 0.000 description 1
- BFLKGEUWQUKMAE-UHFFFAOYSA-N 4-(4-bromoanilino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(Br)C=C1 BFLKGEUWQUKMAE-UHFFFAOYSA-N 0.000 description 1
- NXDUQBJOPNTZBQ-JOCHJYFZSA-N 4-(4-chloro-3-fluoroanilino)-6-[[(1r)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC(NC=2C3=CC(N[C@H]4C5=CC=CC=C5CCC4)=NC=C3N=CC=2C#N)=C1 NXDUQBJOPNTZBQ-JOCHJYFZSA-N 0.000 description 1
- BBDSIOOGKBNSFR-OAQYLSRUSA-N 4-(4-chloro-3-fluoroanilino)-6-[[(1r)-2,3-dihydro-1h-inden-1-yl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC(NC=2C3=CC(N[C@H]4C5=CC=CC=C5CC4)=NC=C3N=CC=2C#N)=C1 BBDSIOOGKBNSFR-OAQYLSRUSA-N 0.000 description 1
- NXDUQBJOPNTZBQ-QFIPXVFZSA-N 4-(4-chloro-3-fluoroanilino)-6-[[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC(NC=2C3=CC(N[C@@H]4C5=CC=CC=C5CCC4)=NC=C3N=CC=2C#N)=C1 NXDUQBJOPNTZBQ-QFIPXVFZSA-N 0.000 description 1
- BBDSIOOGKBNSFR-NRFANRHFSA-N 4-(4-chloro-3-fluoroanilino)-6-[[(1s)-2,3-dihydro-1h-inden-1-yl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC(NC=2C3=CC(N[C@@H]4C5=CC=CC=C5CC4)=NC=C3N=CC=2C#N)=C1 BBDSIOOGKBNSFR-NRFANRHFSA-N 0.000 description 1
- GESOMBGRSQVZJX-MRXNPFEDSA-N 4-(4-chloro-3-fluoroanilino)-6-[[(2r)-1-ethylpyrrolidin-2-yl]methylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound CCN1CCC[C@@H]1CNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=C(Cl)C(F)=C1 GESOMBGRSQVZJX-MRXNPFEDSA-N 0.000 description 1
- GESOMBGRSQVZJX-INIZCTEOSA-N 4-(4-chloro-3-fluoroanilino)-6-[[(2s)-1-ethylpyrrolidin-2-yl]methylamino]-1,7-naphthyridine-3-carbonitrile Chemical compound CCN1CCC[C@H]1CNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=C(Cl)C(F)=C1 GESOMBGRSQVZJX-INIZCTEOSA-N 0.000 description 1
- BKPDBOFXHPBMFZ-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 BKPDBOFXHPBMFZ-UHFFFAOYSA-N 0.000 description 1
- QFMRWLRDJBLKND-UHFFFAOYSA-N 4-(4-chloroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 QFMRWLRDJBLKND-UHFFFAOYSA-N 0.000 description 1
- GTXJRLVLCOZRHS-UHFFFAOYSA-N 4-(4-fluoroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 GTXJRLVLCOZRHS-UHFFFAOYSA-N 0.000 description 1
- IBKZHDHIAWUWPL-UHFFFAOYSA-N 4-(4-methoxyanilino)-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 IBKZHDHIAWUWPL-UHFFFAOYSA-N 0.000 description 1
- OZSMUXCYZXFQPN-UHFFFAOYSA-N 4-(4-phenylsulfanylanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(SC=4C=CC=CC=4)=CC=3)C(C#N)=CN=C2C=NC=1NCC1=CC=CN=C1 OZSMUXCYZXFQPN-UHFFFAOYSA-N 0.000 description 1
- GDYFDXDATVPPDR-UHFFFAOYSA-N 4-(benzenesulfonyl)aniline Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=CC=C1 GDYFDXDATVPPDR-UHFFFAOYSA-N 0.000 description 1
- BJYAUSLHGVSLKK-UHFFFAOYSA-N 4-(cyclopentylamino)-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1CCCC1 BJYAUSLHGVSLKK-UHFFFAOYSA-N 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- PHRJQBHYYBBVSB-UHFFFAOYSA-N 4-[(3-chloro-4-fluorophenyl)methylamino]-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1CNC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 PHRJQBHYYBBVSB-UHFFFAOYSA-N 0.000 description 1
- MOLUQXWMPHUQMP-UHFFFAOYSA-N 4-[(3-chloro-4-fluorophenyl)methylamino]-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NCC1=CC=C(F)C(Cl)=C1 MOLUQXWMPHUQMP-UHFFFAOYSA-N 0.000 description 1
- IYMNZBHZVWJNOK-UHFFFAOYSA-N 4-[3-(furan-2-yl)anilino]-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=C(C=CC=3)C=3OC=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCOCC1 IYMNZBHZVWJNOK-UHFFFAOYSA-N 0.000 description 1
- LKGGTYHCRPVGHW-UHFFFAOYSA-N 4-[4-(benzenesulfonyl)anilino]-6-(2-morpholin-4-ylethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C=C(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)C=CC=1S(=O)(=O)C1=CC=CC=C1 LKGGTYHCRPVGHW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JUUYPIPTLXPQLH-UHFFFAOYSA-N 4-anilino-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC=CC=3)C(C#N)=CN=C2C=NC=1NCC1=CC=CN=C1 JUUYPIPTLXPQLH-UHFFFAOYSA-N 0.000 description 1
- KONGNJQVNXHVMN-UHFFFAOYSA-N 4-anilino-6-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=CC=C1 KONGNJQVNXHVMN-UHFFFAOYSA-N 0.000 description 1
- WDTRNCFZFQIWLM-UHFFFAOYSA-N 4-benzylaniline Chemical compound C1=CC(N)=CC=C1CC1=CC=CC=C1 WDTRNCFZFQIWLM-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- TZQVSGOOKNNDFU-UHFFFAOYSA-N 4-phenylsulfanylaniline Chemical compound C1=CC(N)=CC=C1SC1=CC=CC=C1 TZQVSGOOKNNDFU-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- FLLHMTSPFGSTJC-UHFFFAOYSA-N 6-(2-morpholin-4-ylethoxy)-4-(3-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound CC(C)C1=CC=CC(NC=2C3=CC(OCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 FLLHMTSPFGSTJC-UHFFFAOYSA-N 0.000 description 1
- MJYPKSHFJYSQJY-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(3-phenoxyanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=C(OC=4C=CC=CC=4)C=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCOCC1 MJYPKSHFJYSQJY-UHFFFAOYSA-N 0.000 description 1
- PLDMBHRXTSGSNU-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(3-prop-1-ynylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound CC#CC1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 PLDMBHRXTSGSNU-UHFFFAOYSA-N 0.000 description 1
- ZGQWKKRTPMAEBC-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(3-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound CC(C)C1=CC=CC(NC=2C3=CC(NCCN4CCOCC4)=NC=C3N=CC=2C#N)=C1 ZGQWKKRTPMAEBC-UHFFFAOYSA-N 0.000 description 1
- CVOKRHSRVWWAME-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(4-nitroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCCN1CCOCC1 CVOKRHSRVWWAME-UHFFFAOYSA-N 0.000 description 1
- ZNRZUORPKFAERX-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(4-phenylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(=CC=3)C=3C=CC=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCOCC1 ZNRZUORPKFAERX-UHFFFAOYSA-N 0.000 description 1
- HIASHEATKNRFJC-UHFFFAOYSA-N 6-(2-morpholin-4-ylethylamino)-4-(4-phenylsulfanylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=CC(SC=4C=CC=CC=4)=CC=3)C(C#N)=CN=C2C=NC=1NCCN1CCOCC1 HIASHEATKNRFJC-UHFFFAOYSA-N 0.000 description 1
- HPUWKUUCVHQNGX-UHFFFAOYSA-N 6-(3-chloro-4-fluoroanilino)-4-(cyclopentylamino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(N=CC1=NC=C2C#N)=CC1=C2NC1CCCC1 HPUWKUUCVHQNGX-UHFFFAOYSA-N 0.000 description 1
- NGQDSIIBTBUSAP-UHFFFAOYSA-N 6-(benzylamino)-4-(3-chloro-4-fluoroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CC=C1 NGQDSIIBTBUSAP-UHFFFAOYSA-N 0.000 description 1
- QCUUAZXCXKCUCC-UHFFFAOYSA-N 6-(pyridin-3-ylmethylamino)-4-[3-(trifluoromethoxy)anilino]-1,7-naphthyridine-3-carbonitrile Chemical compound FC(F)(F)OC1=CC=CC(NC=2C3=CC(NCC=4C=NC=CC=4)=NC=C3N=CC=2C#N)=C1 QCUUAZXCXKCUCC-UHFFFAOYSA-N 0.000 description 1
- SVXBHYBKJYCICH-UHFFFAOYSA-N 6-(pyridin-3-ylmethylamino)-4-[4-(trifluoromethoxy)anilino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 SVXBHYBKJYCICH-UHFFFAOYSA-N 0.000 description 1
- YRIRBYAHACHWAQ-UHFFFAOYSA-N 6-[(2-amino-6-fluorophenyl)methylamino]-4-(3-chloro-4-fluoroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound NC1=CC=CC(F)=C1CNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YRIRBYAHACHWAQ-UHFFFAOYSA-N 0.000 description 1
- ZLFMIFSITLEZLH-UHFFFAOYSA-N 6-[(4-methoxyphenyl)methylamino]-4-(3-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1CNC(N=CC1=NC=C2C#N)=CC1=C2NC1=CC=CC(C(C)C)=C1 ZLFMIFSITLEZLH-UHFFFAOYSA-N 0.000 description 1
- WYRYPKHMUJUPOV-UHFFFAOYSA-N 6-[benzyl(methyl)amino]-4-(3-chloro-4-fluoroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C2=C(NC=3C=C(Cl)C(F)=CC=3)C(C#N)=CN=C2C=NC=1N(C)CC1=CC=CC=C1 WYRYPKHMUJUPOV-UHFFFAOYSA-N 0.000 description 1
- PQUBDEVGISBPMV-UHFFFAOYSA-N 6-amino-4-(3-chloro-4-fluoroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(N)=CC2=C1NC1=CC=C(F)C(Cl)=C1 PQUBDEVGISBPMV-UHFFFAOYSA-N 0.000 description 1
- QAJYCQZQLVENRZ-UHFFFAOYSA-N 6-chloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1 QAJYCQZQLVENRZ-UHFFFAOYSA-N 0.000 description 1
- GMJGSURRAUHKCA-UHFFFAOYSA-N 6-fluoro-4-(3-fluoroanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound FC1=CC=CC(NC=2C3=CC(F)=NC=C3N=CC=2C#N)=C1 GMJGSURRAUHKCA-UHFFFAOYSA-N 0.000 description 1
- NKXVYVXYRXLSRL-UHFFFAOYSA-N 6-fluoro-4-(3-phenoxyanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=1)=CC=CC=1OC1=CC=CC=C1 NKXVYVXYRXLSRL-UHFFFAOYSA-N 0.000 description 1
- HDOSMKFDLUTPGB-UHFFFAOYSA-N 6-fluoro-4-(4-phenoxyanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=C1)=CC=C1OC1=CC=CC=C1 HDOSMKFDLUTPGB-UHFFFAOYSA-N 0.000 description 1
- IDXUZWCLBXQAHG-UHFFFAOYSA-N 6-fluoro-4-(4-phenoxyanilino)-1,7-naphthyridine-3-carbonitrile 6-(2-morpholin-4-ylethylamino)-4-(4-phenoxyanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound FC=1C=C2C(=C(C=NC2=CN1)C#N)NC1=CC=C(C=C1)OC1=CC=CC=C1.N1(CCOCC1)CCNC=1C=C2C(=C(C=NC2=CN1)C#N)NC1=CC=C(C=C1)OC1=CC=CC=C1 IDXUZWCLBXQAHG-UHFFFAOYSA-N 0.000 description 1
- QTCILYIEHYVBJL-UHFFFAOYSA-N 6-fluoro-4-(4-phenylsulfanylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC(C=C1)=CC=C1SC1=CC=CC=C1 QTCILYIEHYVBJL-UHFFFAOYSA-N 0.000 description 1
- NIRKRWRLDBSBFL-UHFFFAOYSA-N 6-fluoro-4-(4-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound C1=CC(C(C)C)=CC=C1NC1=C(C#N)C=NC2=CN=C(F)C=C12 NIRKRWRLDBSBFL-UHFFFAOYSA-N 0.000 description 1
- ZCPSCGUZZUMYFK-UHFFFAOYSA-N 6-fluoro-4-(4-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile 6-(2-morpholin-4-ylethylamino)-4-(4-propan-2-ylanilino)-1,7-naphthyridine-3-carbonitrile Chemical compound FC=1C=C2C(=C(C=NC2=CN1)C#N)NC1=CC=C(C=C1)C(C)C.C(C)(C)C1=CC=C(C=C1)NC1=C(C=NC2=CN=C(C=C12)NCCN1CCOCC1)C#N ZCPSCGUZZUMYFK-UHFFFAOYSA-N 0.000 description 1
- DNOXMYNWBDTLSI-UHFFFAOYSA-N 6-fluoro-4-[4-(trifluoromethyl)anilino]-1,7-naphthyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(C(F)(F)F)C=C1 DNOXMYNWBDTLSI-UHFFFAOYSA-N 0.000 description 1
- WBUDZPOEJPHCNH-UHFFFAOYSA-N 6-fluoro-n-[4-(trifluoromethyl)phenyl]-1,7-naphthyridin-4-amine Chemical compound C1=CN=C2C=NC(F)=CC2=C1NC1=CC=C(C(F)(F)F)C=C1 WBUDZPOEJPHCNH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- DASOZVWHLSWDIS-UHFFFAOYSA-N FC=1C=C2C(=C(C=NC2=CN1)C#N)NC=1C=C2C=CNC2=CC1.N1C=CC2=CC(=CC=C12)NC1=C(C=NC2=CN=C(C=C12)NCCN1CCOCC1)C#N Chemical compound FC=1C=C2C(=C(C=NC2=CN1)C#N)NC=1C=C2C=CNC2=CC1.N1C=CC2=CC(=CC=C12)NC1=C(C=NC2=CN=C(C=C12)NCCN1CCOCC1)C#N DASOZVWHLSWDIS-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
- 102100040615 Homeobox protein MSX-2 Human genes 0.000 description 1
- 101000967222 Homo sapiens Homeobox protein MSX-2 Proteins 0.000 description 1
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- BHQPQFHMPBEFST-UHFFFAOYSA-N NC=1C=C(C=CC1)NC1=C(C=NC2=CN=C(C=C12)NCCN1CCOCC1)C#N.C(#N)C=1C=NC2=CN=C(C=C2C1NC=1C=C(C=CC1)NS(=O)(=O)C)NCCN1CCOCC1 Chemical compound NC=1C=C(C=CC1)NC1=C(C=NC2=CN=C(C=C12)NCCN1CCOCC1)C#N.C(#N)C=1C=NC2=CN=C(C=C2C1NC=1C=C(C=CC1)NS(=O)(=O)C)NCCN1CCOCC1 BHQPQFHMPBEFST-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- UNRBEYYLYRXYCG-SSDOTTSWSA-N [(2r)-1-ethylpyrrolidin-2-yl]methanamine Chemical compound CCN1CCC[C@@H]1CN UNRBEYYLYRXYCG-SSDOTTSWSA-N 0.000 description 1
- UNRBEYYLYRXYCG-ZETCQYMHSA-N [(2s)-1-ethylpyrrolidin-2-yl]methanamine Chemical compound CCN1CCC[C@H]1CN UNRBEYYLYRXYCG-ZETCQYMHSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000015842 craniosynostosis 2 Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PQZTVWVYCLIIJY-UHFFFAOYSA-N diethyl(propyl)amine Chemical group CCCN(CC)CC PQZTVWVYCLIIJY-UHFFFAOYSA-N 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 1
- NZBLDCBAOLIPDU-UHFFFAOYSA-N methyl 4-[[3-cyano-6-(pyridin-3-ylmethylamino)-1,7-naphthyridin-4-yl]amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CN=C2NCC1=CC=CN=C1 NZBLDCBAOLIPDU-UHFFFAOYSA-N 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZKONTOQLRAPWED-UHFFFAOYSA-N n-ethylmorpholin-4-amine Chemical compound CCNN1CCOCC1 ZKONTOQLRAPWED-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- ATGUVEKSASEFFO-UHFFFAOYSA-N p-aminodiphenylamine Chemical compound C1=CC(N)=CC=C1NC1=CC=CC=C1 ATGUVEKSASEFFO-UHFFFAOYSA-N 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- LMRCKXYHPYNEJV-UHFFFAOYSA-N piperazine;piperidine Chemical compound C1CCNCC1.C1CNCCN1 LMRCKXYHPYNEJV-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical compound C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- QSYTWBKZNNEKPN-UHFFFAOYSA-N tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCN)CC1 QSYTWBKZNNEKPN-UHFFFAOYSA-N 0.000 description 1
- SIPFWMSOIPIUHS-UHFFFAOYSA-N tert-butyl 4-[2-[[4-(4-benzylanilino)-3-cyano-1,7-naphthyridin-6-yl]amino]ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCNC(N=CC1=NC=C2C#N)=CC1=C2NC(C=C1)=CC=C1CC1=CC=CC=C1 SIPFWMSOIPIUHS-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical group CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68204405P | 2005-05-18 | 2005-05-18 | |
| US60/682,044 | 2005-05-18 | ||
| PCT/US2006/018996 WO2006124944A1 (en) | 2005-05-18 | 2006-05-17 | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2608362A1 true CA2608362A1 (en) | 2006-11-23 |
Family
ID=36972841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002608362A Abandoned CA2608362A1 (en) | 2005-05-18 | 2006-05-17 | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7432279B2 (en:Method) |
| EP (1) | EP1881981A1 (en:Method) |
| JP (1) | JP2008540667A (en:Method) |
| CN (1) | CN101223170A (en:Method) |
| AU (1) | AU2006247315A1 (en:Method) |
| BR (1) | BRPI0611521A2 (en:Method) |
| CA (1) | CA2608362A1 (en:Method) |
| MX (1) | MX2007014258A (en:Method) |
| WO (1) | WO2006124944A1 (en:Method) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101810265B1 (ko) | 2010-04-02 | 2017-12-18 | 세노믹스, 인코포레이티드 | 단맛 향미 개질제 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| JP6026427B2 (ja) * | 2010-12-17 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換６，６−縮合窒素複素環化合物及びその使用 |
| MY179876A (en) | 2011-08-12 | 2020-11-18 | Firmenich Incorporated | Sweet flavor modifier |
| CN102408426B (zh) * | 2011-09-14 | 2013-07-10 | 湖南有色凯铂生物药业有限公司 | 取代的芳香脲类化合物及其作为抗癌药物的应用 |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) * | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US20150297573A1 (en) | 2012-10-24 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL |
| WO2014204261A1 (ko) * | 2013-06-21 | 2014-12-24 | 사회복지법인 삼성생명공익재단 | Tpl2의 발현억제제 또는 활성억제제를 유효성분으로 포함하는 신세포암의 예방 또는 치료용 약학적 조성물 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| CA2943682C (en) | 2014-03-26 | 2024-02-13 | Astex Therapeutics Ltd | Combinations of fgfr and cmet inhibitors and their use for the treatmentof cancer |
| SI3122359T1 (sl) | 2014-03-26 | 2021-05-31 | Astex Therapeutics Ltd. | Kombinacije inhibitorja FGFR in inhibitorja IGF1R |
| BR112017008738B1 (pt) | 2014-11-07 | 2021-06-15 | Firmenich Incorporated | Ácidos 4-amino-5-(ciclohexilóxi)quinolina-3-carboxílicos substituídos como modificadores de sabores adoçantes |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| SG11201702041PA (en) * | 2015-07-06 | 2017-04-27 | Gilead Sciences Inc | Cot modulators and methods of use thereof |
| ES2849953T3 (es) | 2015-07-06 | 2021-08-24 | Gilead Sciences Inc | 6-amino-quinolina-3-carbonitrilos como moduladores de cot |
| LT3353164T (lt) | 2015-09-23 | 2022-01-25 | Janssen Pharmaceutica, N.V. | Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui |
| HRP20201157T1 (hr) | 2015-09-23 | 2020-11-13 | Janssen Pharmaceutica N.V. | Triciklički heterocikli za liječenje raka |
| ES2800339T3 (es) | 2016-06-30 | 2020-12-29 | Gilead Sciences Inc | 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos |
| TW202235416A (zh) | 2019-06-14 | 2022-09-16 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| ES3001984T3 (en) | 2019-12-24 | 2025-03-06 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| CA3175102A1 (en) * | 2020-03-13 | 2021-09-16 | Suzhou Zanrong Pharma Ltd. | Erbb receptor inhibitors as anti-tumor agents |
| WO2021202224A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| AU2021245924B2 (en) | 2020-04-02 | 2024-02-29 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
| CA3181922A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7654118B2 (ja) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| JP2024546851A (ja) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE264328T1 (de) * | 1999-04-21 | 2004-04-15 | Wyeth Corp | Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen |
| US6355636B1 (en) * | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US6548496B2 (en) * | 1999-04-21 | 2003-04-15 | American Cyanamid Company | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
-
2006
- 2006-05-17 BR BRPI0611521-7A patent/BRPI0611521A2/pt not_active Application Discontinuation
- 2006-05-17 AU AU2006247315A patent/AU2006247315A1/en not_active Abandoned
- 2006-05-17 JP JP2008512451A patent/JP2008540667A/ja not_active Withdrawn
- 2006-05-17 CN CNA2006800261965A patent/CN101223170A/zh active Pending
- 2006-05-17 CA CA002608362A patent/CA2608362A1/en not_active Abandoned
- 2006-05-17 EP EP06759971A patent/EP1881981A1/en not_active Withdrawn
- 2006-05-17 MX MX2007014258A patent/MX2007014258A/es active IP Right Grant
- 2006-05-17 WO PCT/US2006/018996 patent/WO2006124944A1/en not_active Ceased
- 2006-05-18 US US11/436,328 patent/US7432279B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006124944A1 (en) | 2006-11-23 |
| EP1881981A1 (en) | 2008-01-30 |
| MX2007014258A (es) | 2008-01-22 |
| AU2006247315A1 (en) | 2006-11-23 |
| BRPI0611521A2 (pt) | 2010-09-14 |
| US20060276498A1 (en) | 2006-12-07 |
| US7432279B2 (en) | 2008-10-07 |
| JP2008540667A (ja) | 2008-11-20 |
| CN101223170A (zh) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7432279B2 (en) | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | |
| US7799922B2 (en) | Aminoquinoline derivatives and their use as adenosine A3 ligands | |
| US20120184548A1 (en) | Carboxylic acid aryl amides | |
| US20030220357A1 (en) | Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof | |
| CA2729965A1 (en) | Fused heterocyclyc inhibitor compounds | |
| WO2011082098A1 (en) | Lysine and arginine methyltransferase inhibitors for treating cancer | |
| JPWO2012008563A1 (ja) | 含窒素芳香族複素環誘導体 | |
| JP2008540656A (ja) | Ｔｐｌ２キナーゼの３−シアノキノリン阻害物質ならびにそれを製造および使用する方法 | |
| KR20140057614A (ko) | Dyrk1 억제제 및 이의 용도 | |
| JP2017524703A (ja) | ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用 | |
| AU2004264937A1 (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| KR20160116010A (ko) | 나프틸아미드계 화합물, 이의 제조 방법과 용도 | |
| CA2631438A1 (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
| WO2015081783A1 (zh) | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 | |
| CN101115744A (zh) | 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐 | |
| WO2007018941A2 (en) | Pyrimidyl-thiophene derivatives | |
| JP7110335B2 (ja) | プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体 | |
| CN101239945B (zh) | 氨基喹啉衍生物和它们作为腺苷a3配体的用途 | |
| AU2018278284A1 (en) | Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors | |
| RU2317290C2 (ru) | Производные аминохинолина и их применение в качестве лигандов аденозина а3 | |
| HK1088261B (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
| HUP0401467A2 (en) | Aminoquinoline derivatives, process for producing them and their use as adenosine a3 ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |